Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Irace, Concetta
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
NCT05893797: A Study of LY8888AX in Participants Using a Connected Insulin Management Platform	Completed	N/A	36	Europe	Insulin Lispro, Humalog Tempo Pen, Tempo Smart Button, Dexcom G6 CGM, Glooko Research Medical App (RMA)	Eli Lilly and Company	Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin	09/24	09/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Irace, Concetta
NCT04628481 / 2020-001926-71: A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function	Active, not recruiting	2	140	Europe, US, RoW	Ladarixin, allosteric inhibitor of CXCL8 (IL-8), CXCR1 and CXCR2 receptors, Placebo	Dompé Farmaceutici S.p.A, Dompe farmaceutici s.p.a.	Recent Onset type1 Diabetes	04/24	04/26
NCT05893797: A Study of LY8888AX in Participants Using a Connected Insulin Management Platform	Completed	N/A	36	Europe	Insulin Lispro, Humalog Tempo Pen, Tempo Smart Button, Dexcom G6 CGM, Glooko Research Medical App (RMA)	Eli Lilly and Company	Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin	09/24	09/24